European Society
For Medical Oncology

Findings from the FLAURA2 study

Findings from the European MCL Elderly study

New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated

Findings from the TAB study

Evidence for efficacy is evaluated in CAPItello-291 study

Final results of a preplanned analysis at a 10-year follow-up of H10 study

Findings from an exploratory post hoc analysis of the subgroup of patients with BRCA alterations in PROfound study 

Evidence for efficacy is based on the results from the FRESCO-2 and FRESCO studies

It is intended for the treatment of adults with advanced NSCLC with KRAS G12C mutation and disease progression after at least one prior systemic therapy

The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component

The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.

Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society

As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment

Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain

Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas

More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023  

Artificial intelligence (AI) has made a grand entrance into the public debate this year, but researchers have long been investigating its potential to transform cancer care and improve patient outcomes

Under the promise to “Disseminating innovative research for optimal cancer care” as this year’s tagline reads, the ESMO Congress 2023 will be held in Madrid between 20-24 October 2023 with a virtual component to allow as many people as possible to attend.

The ESMO Award for Immuno-Oncology 2023 was bestowed to Steven A. Rosenberg in recognition of his exceptional contribution to the field of cancer immunology research.

After five days filled with practice-changing data, intense discussions and educational sessions addressing the needs and issues currently arising for oncology professionals and impacting patients with cancer worldwide, the ESMO Congress 2023 today sent home its more than 33,000 participants from 144 countries with plenty of food for thought and ample material to enrich their medical practice.

ESMO and ASCO, the two largest professional organisations for oncologists, have released the 2023 edition of their joint recommendations for the Curriculum for Training in Medical Oncology

ESMO expresses deep sorrow about all the ongoing tragic events that continue to happen in many parts of the world and joins the voices pressing for a rapid return to peace

We regret to inform you of an embargo breach in which late-breaking abstract data has been made available online ahead of the official publication schedule

Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose 

ESMO President will act as an Advisor

The very first expert-based guidance for reporting real-world evidence studies specifically for oncology, “ESMO Guidance for Reporting Oncology real-World evidence (GROW)", has been developed by ESMO, together with the valuable contribution of external stakeholders.

Committed to delivering high-quality medical science and to helping the oncology community to stay up to date with the latest developments in the field, ESMO has expanded its portfolio of journals.